Overview

Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia

Status:
Recruiting
Trial end date:
2021-10-28
Target enrollment:
Participant gender:
Summary
Preliminarily investigate the safety and efficacy of two doses of hzVSF-v13 + SOC vs. placebo + SOC for the treatment of COVID-19 pneumonia.
Phase:
Phase 2
Details
Lead Sponsor:
ImmuneMed, Inc.
Treatments:
Antibodies, Monoclonal